Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients
Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Journal of Virus Eradication |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2055664024000335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585113515327488 |
|---|---|
| author | Jiayi Wang Lingyao Du Dongmei Zhang Chen Zhou Yilan Zeng Miao Liu Xing Cheng Xiaona Song Han Chen Ning Han Enqiang Chen Hong Tang |
| author_facet | Jiayi Wang Lingyao Du Dongmei Zhang Chen Zhou Yilan Zeng Miao Liu Xing Cheng Xiaona Song Han Chen Ning Han Enqiang Chen Hong Tang |
| author_sort | Jiayi Wang |
| collection | DOAJ |
| description | Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection. Methods: In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China. Patients included adults with with CHC and any genotype (GT), with or without cirrhosis, hepatocellular carcinoma (HCC), HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection. Patients were administered SOF/VEL (400/100 mg) ± ribavirin (RBV) once daily for 12 weeks. The primary efficacy endpoint was sustained virological response at post-treatment week 12 (SVR12). Adverse events (AEs) were evaluated during treatment. Results: The study included 483 patients with HCV genotypes 1, 2, 3, 6 and uncertain ones. Among them, 35.4 % (171/483, ITT) and 36.7 % (166/452, mITT) received SOF/VEL + RBV. At the end of treatment , 99.2 % (ITT, 479/483) and 99.1 % (mITT, 448/452) of patients had undetectable HCV RNA. SVR12 rates were 92.8 % [intention to treat (ITT), 448/483] and 99.1 % [modified ITT (mITT), 448/452]. In the mITT analysis, SVR12 for patients with HCV GT3b, those with cirrhosis or HCC, and those coinfected with HBV/HIV was 99.2 % (130/131), 99.4 % (168/169), and 97.6 % (40/41), respectively. The albumin-bilirubin (ALBI) (−3.01 vs. −3.18 P < 0.001), Fibrosis-4 (FIB4) Index (2.53 vs. 1.88, P = 0.004) and AST to Platelet Ratio Index (APRI) (0.99 vs. 0.44, P < 0.001) scores showed a significant decrease from baseline to SVR12. No patients experienced grade 3–5 AEs. Conclusions: Although a high proportion of patients included in this study had HCV GT3b, cirrhosis, HCC, or HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection, SOF/VEL ± RBV was highly effective and well tolerated in Chinese patients with CHC. |
| format | Article |
| id | doaj-art-0da4971ede154aa7b5df623854e5a5b2 |
| institution | Kabale University |
| issn | 2055-6640 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Virus Eradication |
| spelling | doaj-art-0da4971ede154aa7b5df623854e5a5b22025-01-27T04:21:50ZengElsevierJournal of Virus Eradication2055-66402024-12-01104100571Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patientsJiayi Wang0Lingyao Du1Dongmei Zhang2Chen Zhou3Yilan Zeng4Miao Liu5Xing Cheng6Xiaona Song7Han Chen8Ning Han9Enqiang Chen10Hong Tang11Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaPublic Health Clinical Center of Chengdu, Chengdu, Sichuan, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, ChinaCenter of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Corresponding author. Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Laboratory of Infectious and Liver Diseases, Institution of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China; Corresponding author. Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, 610041, China.Background: Hepatitis C virus (HCV) eradication with sofosbuvir/velpatasvir (SOF/VEL) represents a significant advancement, offering hope for eliminating the virus in diverse patient populations. But real-world data on its effectiveness and safety remains scarce for patients with chronic hepatitis C (CHC) in China, especially those with HCV GT3b, cirrhosis, hepato-cellular carcinoma (HCC), or HCV/hepatitis B (HBV), HCV/HIV, or HCV/HBV/HIV coinfection. Methods: In this real-world prospective observational study, we recruited patients from the West China Hospital and Public Health Clinical Center of Chengdu in China. Patients included adults with with CHC and any genotype (GT), with or without cirrhosis, hepatocellular carcinoma (HCC), HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection. Patients were administered SOF/VEL (400/100 mg) ± ribavirin (RBV) once daily for 12 weeks. The primary efficacy endpoint was sustained virological response at post-treatment week 12 (SVR12). Adverse events (AEs) were evaluated during treatment. Results: The study included 483 patients with HCV genotypes 1, 2, 3, 6 and uncertain ones. Among them, 35.4 % (171/483, ITT) and 36.7 % (166/452, mITT) received SOF/VEL + RBV. At the end of treatment , 99.2 % (ITT, 479/483) and 99.1 % (mITT, 448/452) of patients had undetectable HCV RNA. SVR12 rates were 92.8 % [intention to treat (ITT), 448/483] and 99.1 % [modified ITT (mITT), 448/452]. In the mITT analysis, SVR12 for patients with HCV GT3b, those with cirrhosis or HCC, and those coinfected with HBV/HIV was 99.2 % (130/131), 99.4 % (168/169), and 97.6 % (40/41), respectively. The albumin-bilirubin (ALBI) (−3.01 vs. −3.18 P < 0.001), Fibrosis-4 (FIB4) Index (2.53 vs. 1.88, P = 0.004) and AST to Platelet Ratio Index (APRI) (0.99 vs. 0.44, P < 0.001) scores showed a significant decrease from baseline to SVR12. No patients experienced grade 3–5 AEs. Conclusions: Although a high proportion of patients included in this study had HCV GT3b, cirrhosis, HCC, or HCV/HBV, HCV/HIV, or HCV/HBV/HIV coinfection, SOF/VEL ± RBV was highly effective and well tolerated in Chinese patients with CHC.http://www.sciencedirect.com/science/article/pii/S2055664024000335Hepatitis CSofosbuvir-velpatasvir (SOF/VEL)RibavirinGenotypeCirrhosisCoinfection |
| spellingShingle | Jiayi Wang Lingyao Du Dongmei Zhang Chen Zhou Yilan Zeng Miao Liu Xing Cheng Xiaona Song Han Chen Ning Han Enqiang Chen Hong Tang Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients Journal of Virus Eradication Hepatitis C Sofosbuvir-velpatasvir (SOF/VEL) Ribavirin Genotype Cirrhosis Coinfection |
| title | Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients |
| title_full | Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients |
| title_fullStr | Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients |
| title_full_unstemmed | Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients |
| title_short | Real-life study on the effectiveness and safety of sofosbuvir/velpatasvir-based antiviral agents for hepatitis C eradication in Chinese patients |
| title_sort | real life study on the effectiveness and safety of sofosbuvir velpatasvir based antiviral agents for hepatitis c eradication in chinese patients |
| topic | Hepatitis C Sofosbuvir-velpatasvir (SOF/VEL) Ribavirin Genotype Cirrhosis Coinfection |
| url | http://www.sciencedirect.com/science/article/pii/S2055664024000335 |
| work_keys_str_mv | AT jiayiwang reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT lingyaodu reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT dongmeizhang reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT chenzhou reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT yilanzeng reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT miaoliu reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT xingcheng reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT xiaonasong reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT hanchen reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT ninghan reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT enqiangchen reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients AT hongtang reallifestudyontheeffectivenessandsafetyofsofosbuvirvelpatasvirbasedantiviralagentsforhepatitisceradicationinchinesepatients |